BioGlue Aesthetic adhesive conducted under a U.S. IDE which
demonstrated raised brow position in 89% of patients at 6 months.
BioForm is working with its clinical advisors and FDA to determine the
best design for a pivotal study of BioGlue Aesthetic adhesive to
support U.S. approval.
"We are pleased to report sales performance for the quarter and fiscal year ended June 30, 2008 in line with the guidance we provided in our third quarter fiscal 2008 conference call and earnings release. Our guidance for fiscal year 2009 reflects an expectation that the current dermal filler market softness will persist for two more quarters, with only modest recovery starting thereafter," commented Steve Basta, Chief Executive Officer of BioForm Medical, Inc. "In fiscal 2009, we are focused on training and education to drive clinical confidence among RADIESSE dermal filler users, expanding the RADIESSE filler user base through new account conversions, and developing our future products, which we believe will contribute to accelerating revenue growth in fiscal 2010 and beyond."
BioForm Medical will hold a conference call today at 2:00 pm Pacific Time (5:00 p.m. Eastern Time) to discuss the financial results and guidance. The conference call will be webcast live on the Investor Relations section of BioForm Medical's website at http://www.bioform.com. The conference call may be accessed by dialing 888-287-5530 for callers in the U.S. and 719-785-1786 for international callers. Please notify the operator that you would like to join "BioForm Medical's Fourth Quarter & Fiscal 2008 Earnings Call" and provide the participant code "2257477", if prompted.
About BioForm Medical, Inc.:
BioForm Medical, Inc. is a medical aesthetics company headquartered in
San Mateo, California, developing products that enhance aesthet
|SOURCE BioForm Medical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved